Literature DB >> 8492908

Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons.

S L Dickson1, G Leng, I C Robinson.   

Abstract

The synthetic hexapeptide growth hormone-releasing peptide selectively releases growth hormone in many species including man. Growth hormone-releasing peptide directly stimulates growth hormone release by an action at the level of the pituitary, at a different receptor site to that for the endogenous 44-amino acid peptide, growth hormone-releasing hormone, and when administered with growth hormone-releasing hormone has a synergistic effect. In addition to this pituitary action, we have suggested that the potent in vivo growth hormone-releasing activity of growth hormone-releasing peptide reflects a hypothalamic action and growth hormone-releasing peptide binding sites have been reported to be present in the hypothalamus. We have now found more direct evidence for a hypothalamic action of growth hormone-releasing peptide in two ways. First, we have found that a sub-population of hypothalamic neurons show strongly increased fos expression in response to systemic growth hormone-releasing peptide administration. Fos is the protein product of the immediate early gene, c-fos, which is induced in many neuronal systems following their activation. Second, extracellular recordings from putative growth hormone-releasing hormone neurons in the arcuate nucleus showed that growth hormone-releasing peptide also stimulates the firing of neurons in this area.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8492908     DOI: 10.1016/0306-4522(93)90197-n

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  27 in total

1.  AMPA-sst2 somatostatin receptor interaction in rat hypothalamus requires activation of NMDA and/or metabotropic glutamate receptors and depends on intracellular calcium.

Authors:  Stéphane Peineau; Brigitte Potier; Florence Petit; Pascal Dournaud; Jacques Epelbaum; Robert Gardette
Journal:  J Physiol       Date:  2003-01-01       Impact factor: 5.182

2.  Do growth hormone-releasing peptides act as ghrelin secretagogues?

Authors:  I Ahnfelt-Rønne; J Nowak; U B Olsen
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Central actions of the nonpeptide growth hormone secretagogue GHS-25.

Authors:  A R Bailey; L Gilliver; G Leng; R G Smith
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

4.  Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin.

Authors:  G S Tannenbaum; C Y Bowers
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 5.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 6.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

7.  Brain-endocrine interactions: a microvascular route in the mediobasal hypothalamus.

Authors:  Philippe Ciofi; Maurice Garret; Olivier Lapirot; Pierrette Lafon; Anne Loyens; Vincent Prévot; Jon E Levine
Journal:  Endocrinology       Date:  2009-10-16       Impact factor: 4.736

8.  Ghrelin's control of food reward and body weight in the lateral hypothalamic area is sexually dimorphic.

Authors:  Lorena López-Ferreras; Jennifer E Richard; Rozita H Anderberg; Fredrik H Nilsson; Kajsa Olandersson; Scott E Kanoski; Karolina P Skibicka
Journal:  Physiol Behav       Date:  2017-02-14

9.  Lateral septum growth hormone secretagogue receptor affects food intake and motivation for sucrose reinforcement.

Authors:  Sarah J Terrill; Kaylee D Wall; Nelson D Medina; Calyn B Maske; Diana L Williams
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-03-28       Impact factor: 3.619

10.  GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal.

Authors:  M R A Martins; A C A R Pinto; E Brunner; M R D Silva; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.